Overexpression of activated leukocute cell adhesion molecule in gastric cancer is associated with advanced stages and poor prognosis and miR-9 deregulation

Molecular Medicine Reports

Volumn 11, Issue 3, 2015, Pages 2004-2012

  Ye, Min ^a   Du, Yan Lei ^a   Nie, Yu Qiang ^a   Zhou, Zhi Wei ^b   Cao, Jie ^a   Li, Ying Fei ^a  

^a GUANGZHOU MEDICAL UNIVERSITY   (China)

^b Shenzhen Luohu Hospital Group Luohu People s Hospital   (China)

Author keywords

ALCAM; Gastric cancer; MiR 9; SALCAM

Indexed keywords

ACTIVATED LEUKOCYTE CELL ADHESION MOLECULE; MESSENGER RNA; MICRORNA 9; MICRORNA; MIRN92 MICRORNA, HUMAN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GASTRIC CANCER CELL LINE; GENE OVEREXPRESSION; GENETIC ASSOCIATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRECANCER; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOMACH CANCER; CANCER STAGING; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENETICS; LYMPH NODE METASTASIS; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; PROTEIN TRANSPORT; STOMACH TUMOR; SURVIVAL; TUMOR CELL LINE;

ACTIVATED-LEUKOCYTE CELL ADHESION MOLECULE; ADULT; AGED; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPHATIC METASTASIS; MALE; MICRORNAS; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROTEIN TRANSPORT; RNA, MESSENGER; STOMACH NEOPLASMS; SURVIVAL ANALYSIS;

EID: 84916619845     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2014.2933     Document Type: Article

References (38)

1. Ofori-Acquah SF and King JA: Activated leukocyte cell adhesion molecule: a new paradox in cancer. Transl Res 151: 122-128, 2008.
2. Bowen MA, Patel DD, Li X, et al: Cloning, mapping, and characterization of activated leukocyte-cell adhesion molecule (ALCAM), a CD6 ligand. J Exp Med 181: 2213-2220, 1995.
3. Patel DD, Wee SF, Whichard LP, et al: Identification and characterization of a 100-kD ligand for CD6 on human thymic epithelial cells. J Exp Med 181: 1563-1568, 1995.
4. Bruder SP, Ricalton NS, Boynton RE, et al: Mesenchymal stem cell surface antigen SB-10 corresponds to activated leukocyte cell adhesion molecule and is involved in osteogenic differentiation. J Bone Miner Res 13: 655-663, 1998.
5. Sekine-Aizawa Y, Omori A and Fujita SC: MuSC, a novel member of the immunoglobulin superfamily, is expressed in neurons of a subset of cranial sensory ganglia in the mouse embryo. Eur J Neurosci 10: 2810-2824, 1998.
6. Cortés F, Deschaseaux F, Uchida N, et al: HCA, an immunoglobulin-like adhesion molecule present on the earliest human hematopoietic precursor cells, is also expressed by stromal cells in blood-forming tissues. Blood 93: 826-837, 1999.
7. Fujiwara H, Tatsumi K, Kosaka K, et al: Human blastocysts and endometrial epithelial cells express activated leukocyte cell adhesion molecule (ALCAM/CD166). J Clin Endocrinol Metab 88: 3437-3443, 2003.
8. Weidle UH, Eggle D, Klostermann S and Swart GW: ALCAM/CD166: cancer-related issues. Cancer Genomics Proteomics 7: 231-243, 2010.
9. Kristiansen G, Pilarsky C, Wissmann C, et al: ALCAM/CD166 is up-regulated in low-grade prostate cancer and progressively lost in high-grade lesions. Prostate 54: 34-43, 2003.
10. Weichert W, Knösel T, Bellach J, Dietel M and Kristiansen G: ALCAM/CD166 is overexpressed in colorectal carcinoma and correlates with shortened patient survival. J Clin Pathol 57: 1160-1164, 2004.
11. Hein S, Müller V, Köhler N, et al: Biologic role of activated leukocyte cell adhesion molecule overexpression in breast cancer cell lines and clinical tumor tissue. Breast Cancer Res Treat 129: 347-360, 2011.
12. Kijima N, Hosen N, Kagawa N, et al: CD166/activated leukocyte cell adhesion molecule is expressed on glioblastoma progenitor cells and involved in the regulation of tumor cell invasion. Neuro Oncol 14: 1254-1264, 2012.
13. Ishiguro F, Murakami H, Mizuno T, et al: Membranous expression of activated leukocyte cell adhesion molecule contributes to poor prognosis and malignant phenotypes of non-small-cell lung cancer. J Surg Res 179: 24-32, 2013.
14. Lunter PC, van Kilsdonk JW, van Beek H, et al: Activated leukocyte cell adhesion molecule (ALCAM/CD166/MEMD), a novel actor in invasive growth, controls matrix metalloproteinase activity. Cancer Res 65: 8801-8808, 2005.
15. Ikeda K and Quertermous T: Molecular isolation and characterization of a soluble isoform of activated leukocyte cell adhesion molecule that modulates endothelial cell function. J Biol Chem 279: 55315-55323, 2004.
16. Tachezy M, Zander H, Marx AH, et al: ALCAM (CD166) expression and serum levels in pancreatic cancer. PLoS One 7: e39018, 2012.
17. Tachezy M, Effenberger K, Zander H, et al: ALCAM (CD166) expression and serum levels are markers for poor survival of esophageal cancer patients. Int J Cancer 131: 396-405, 2012.
18. Ambros V: The functions of animal microRNAs. Nature 431: 350-355, 2004.
19. Sethupathy P, Megraw M and Hatzigeorgiou AG: A guide through present computational approaches for the identification of mammalian microRNA targets. Nat Methods 3: 881-886, 2006.
20. Mendes ND, Freitas AT and Sagot MF: Current tools for the identification of miRNA genes and their targets. Nucleic Acids Res 37: 2419-2433, 2009.
21. Wang J, Gu Z, Ni P, et al: NF-kappaB P50/P65 hetero-dimer mediates differential regulation of CD166/ALCAM expression via interaction with micoRNA-9 after serum deprivation, providing evidence for a novel negative auto-regulatory loop. Nucleic Acids Res 39: 6440-6455, 2011.
22. Liu N, Sun Q, Chen J, et al: MicroRNA-9 suppresses uveal melanoma cell migration and invasion through the NF-B1 pathway. Oncol Rep 28: 961-968, 2012.
23. Selcuklu SD, Donoghue MT, Rehmet K, et al: MicroRNA-9 inhibition of cell proliferation and identification of novel miR-9 targets by transcriptome profiling in breast cancer cells. J Biol Chem 287: 29516-29528, 2012.
24. de Martel C, Forman D and Plummer M: Gastric cancer: epidemiology and risk factors. Gastroenterol Clin North Am 42: 219-240, 2013.
25. Ishigami S, Ueno S, Arigami T, et al: Clinical implication of CD166 expression in gastric cancer. J Surg Oncol 103: 57-61, 2011.
26. Lauren P: The two histological main types of gastric carcinoma: Diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification.Acta Pathol Microbiol Scand 64: 31-49, 1965.
27. Lauwers GY, Carneiro F and Graham DY: Gastric carcinoma. In: WHO Classification of tumors of the digestive system Bosman FT, Carneiro F and Hruban RH (eds). IARC Press, Lyon, pp48-58, 2010.
28. van den Oord JJ, van Muijen GN, Weidle UH, Bloemers HP and Swart GW: Activated leukocyte cell adhesion molecule/CD166, a marker of tumor progression in primary malignant melanoma of the skin. Am J Pathol 156: 769-774, 2000.
29. Ishiguro F, Murakami H, Mizuno T, et al: Activated leukocyte cell-adhesion molecule (ALCAM) promotes malignant phenotypes of malignant mesothelioma. J Thorac Oncol 7: 890-899, 2012.
30. van Kempen LC, Nelissen JM, Degen WG, et al: Molecular basis for the homophilic activated leukocyte cell adhesion molecule (ALCAM)-ALCAM interaction. J Biol Chem 276: 25783-25790, 2001.
31. Nelissen JM, Peters IM, de Grooth BG, van Kooyk Y and Figdor CG: Dynamic regulation of activated leukocyte cell adhesion molecule-mediated homotypic cell adhesion through the actin cytoskeleton. Mol Biol Cell 11: 2057-2068, 2000.
32. Jannie KM, Stipp CS and Weiner JA: ALCAM regulates motility, invasiveness, and adherens junction formation in uveal melanoma cells. PLoS One 7: e39330, 2012.
33. Tomita K, van Bokhoven A, Jansen CF, Bussemakers MJ and Schalken JA: Coordinate recruitment of E-cadherin and ALCAM to cell-cell contacts by alpha-catenin. Biochem Biophys Res Commun 267: 870-874, 2000.
34. Mezzanzanica D, Fabbi M, Bagnoli M, et al: Subcellular localization of activated leukocyte cell adhesion molecule is a molecular predictor of survival in ovarian carcinoma patients. Clin Cancer Res 14: 1726-1733, 2008.
35. Rosso O, Piazza T, Bongarzone I, et al: The ALCAM shedding by the metalloprotease ADAM17/TACE is involved in motility of ovarian carcinoma cells. Mol Cancer Res 5: 1246-1253, 2007.
36. Weidle UH, Eggle D and Klostermann S: L1-CAM as a target for treatment of cancer with monoclonal antibodies. Anticancer Res 29: 4919-4931, 2009.
37. Kahlert C, Weber H, Mogler C, et al: Increased expression of ALCAM/CD166 in pancreatic cancer is an independent prognostic marker for poor survival and early tumour relapse. Br J Cancer 101: 457-464, 2009.
38. Bartel DP: MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116: 281-297, 2004.